Amedisys Inc (AMED)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	-9,747	2,648	2,330	112,184	118,609	120,939	140,303	190,873	209,072	220,125	247,100	201,625	183,557	166,157	128,276	127,302	126,800	126,600	123,900	123,500
Revenue (ttm)	US$ in thousands	2,236,382	2,227,658	2,229,409	2,234,331	2,223,199	1,671,704	1,667,201	1,111,979	573,337	567,158	15,793	33,153	518,223	1,014,511	1,507,022	1,979,978	1,955,633	1,889,333	1,810,011	1,726,487
Net profit margin		-0.44%	0.12%	0.10%	5.02%	5.34%	7.23%	8.42%	17.17%	36.47%	38.81%	1,564.62%	608.17%	35.42%	16.38%	8.51%	6.43%	6.48%	6.70%	6.85%	7.15%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $-9,747K ÷ $2,236,382K
= -0.44%

Amedisys Inc.'s net profit margin has shown variability over the past eight quarters. In Q4 2023, the company reported a negative net profit margin of -0.44%, indicating that the company did not generate profit during that period. This is a significant decline compared to the previous quarter (Q3 2023) where the net profit margin was 0.12%.

Looking further back, the net profit margin has been declining since Q1 2023 (5.02%), Q4 2022 (5.34%), and Q3 2022 (5.45%). These declines suggest a potential trend of decreasing profitability over the past few quarters.

Comparing the recent quarters to the earlier quarters of Q2 2022 (6.33%) and Q1 2022 (8.59%), it is evident that the company's profitability has seen a notable decrease in recent periods.

Overall, Amedisys Inc.'s net profit margin analysis illustrates a recent decline in profitability, with the company facing challenges in maintaining consistent levels of profitability. This trend warrants further investigation to identify the underlying causes and explore potential strategies for improving future financial performance.